The Company and Summary of Significant Accounting Policies (Details Narrative) - EUR (€)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accumulated deficit	€ (102,555,000)
Current liabilities exceeding current assets	€ 71,549
Preferred stock shares authorized	5,000,000	5,000,000
Potentially shares issuable	802,780,311	766,180,633
Potentially shares issuable convertible loans	777,030,311	740,430,633
Basic weighted and diluted	303,757,622	303,757,622
Budget description	The overall budget related to the project is US$8,850 with US$7,131 approved for the period of (May 2019 to April 2023). This includes the funds approved for the period of (May 2022 to April 2023) of US$1,616
Grant allocated description	The amounts mentioned in the following statements are purely related to the Company and not to the other partners in the project: The overall portion of the grant allocated to the Company is US$4,650 approved for the period of (May 2019 to April 2023). This includes the funds approved for the period of (May 2022 to April 2023) of US$1,328
Grant Revenue [Member]
Concentration risk percentage	99.00%	99.00%
First Year [Member]
Sub award grant revenue USD	€ 599
Sub award grant revenue euro	542
Sub award project cost USD	743
Second Year [Member]
Sub award grant revenue USD	1,048
Sub award grant revenue euro	909
Sub award project cost USD	1,519
Third Year [Member]
Sub award grant revenue USD	986
Sub award grant revenue euro	899
Sub award project cost USD	1,078
Fourth Year [Member]
Sub award grant revenue USD	296
Sub award grant deferred revenue USD	7
Sub award project cost USD	€ 1,328
Stock Option [Member]
Potentially shares issuable	25,750,000	25,750,000